BHVN vs GNPX: stock comparison

Biohaven Ltd.

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Open BHVN dashboard ↗

Genprex, Inc. Common Stock

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Open GNPX dashboard ↗

BHVN vs GNPX

Compare the businesses

Biohaven Ltd.

Genprex, Inc. Common Stock

Sign in to keep comparing stocks